Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a new patent which provides additional patent claims that protect the use of its DehydraTECH™ technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix and serve beverage formats.

This signifies another addition to Lexaria’s first patent family, under which eight US patents have previously been granted. The patent application number is 16/497,920 under the title “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof”. As has been Lexaria’s experience in the past, the Company expects the formal granting of the new patent within roughly one hundred days or less.


Lexaria also announces that it has issued: 2,538,000 stock options to certain employees, consultants, directors and officers of the Company for the purchase of up to 2,538,000 common shares of the Company at an exercise price of US$0.32; and 700,000 stock options to an executive officer who also holds over 10% of the Company’s issued share capital for the purchase of up to 700,000 common shares of the Company at an exercise price of US$0.34 (collectively the “Options”). The Options are being issued pursuant to the Company’s shareholder approved Equity Incentive Plan whereby the exercise price of any Options issued to a person holding 10% or more of the Company’s issued share capital must be equal to 110% of the fair market value of the Company’s shares. The Options are exercisable for a period of five years expiring on April 23, 2025, with some issuances being subject to certain vesting provisions.

The option shares will be subject to a four month hold period as prescribed by Canadian Securities Exchange policies.

About Lexaria

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

www.lexariabioscience.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.
Chris Bunka, CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling products containing cannabinoids, anti-viral drugs or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-produced products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Click here to connect with Lexaria Bioscience Corp. (CSE:LXX, OCT:LXRP) for an Investor Presentation.

Source

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness Company offering premium probiotic supplements and products containing CBD, announces that it has promoted Maria Leal, the Company’s Vice President and Controller, to Interim Chief Financial Officer.

Ms. Leal holds a CPA and an MBA and has a strong track record in financial management having served in various senior financial accounting positions during her more than 20-year career. Ms. Leal has been with HempFusion since July 2019 and has been instrumental in all financial reporting aspects for the Company.

Keep reading... Show less

Centurion to acquire a Disruptive Water-Soluble Cannabinoid Technology Platform Delivering Rapid Onset, Increased Bioavailability, Premium Taste Profiles and Highly Competitive Cost Structure

Centurion Minerals Ltd. (TSXV: CTN) (“Centurion”, or the “Company”) wishes to provide an update on its previously announced Amalgamation Agreement (the “Agreement”), with HAI Beverages Inc. (“HAI”), whereby Centurion is acquiring 100% of the outstanding shares and assets of a wholly-owned subsidiary of HAI (“NewHAI”) in exchange for common shares of Centurion (the “Acquisition” or “Transaction”). NewHAI holds all material assets of HAI and the Acquisition will constitute a reverse take-over (“RTO”) of the Company.

Keep reading... Show less

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received approval to graduate  to Tier 1 Issuer status on the TSX Venture Exchange (the “TSXV”), effective June 18, 2021 .

Keep reading... Show less

Harvest Health & Recreation Inc. (“Harvest”) ( CSE: HARV OTCQX: HRVSF ), a vertically integrated cannabis company and multi-state operator in the U.S., today announced the opening of two new medical dispensaries in Lehigh Acres and North Miami Beach, Florida .

Harvest of Lehigh Acres is located at 1315 Homestead Road N Ste B, Lehigh Acres .
Harvest of North Miami Beach is located at 15100 Biscayne Blvd, North Miami Beach .
Both locations are open Monday through Saturday from 9:00 am to 8:00 pm and Sunday from 10:00 am to 7:00 pm .

Keep reading... Show less

Canbud Distribution Corp. (CSE: CBDX) (“Canbud” or the “Corporation”) is pleased to announce that, further to its news release of May 27, 2021, it has entered into a definitive acquisition agreement (the “Acquisition Agreement”) with Molecular Science Corp. (“MSC”) and 2847719 Ontario Inc. (“Subco”), a wholly-owned subsidiary of Canbud, pursuant to which it agreed to acquire all of the outstanding securities of MSC by way of a three-cornered amalgamation (the “Transaction”). The Transaction is subject to receipt of all necessary regulatory approvals, including, as applicable, approval of the Canadian Securities Exchange (“CSE”), and certain other conditions as described below.

About MSC

Keep reading... Show less